AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12269969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 350 mg, infused intravenously three times a week for 4 weeks
Number of subjects: 22
Study 12269969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) 250 mg, infused intravenously for patients weighing 36-50 kg
Number of subjects: 22
Study 12269969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alicaforsen (ISIS 2302) (all doses)
Number of subjects: 22
Study 10194609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline formulation (200 mg anhydrous theophylline)
Number of subjects: 6
Study 10194609 — intervention group
Group type: COMPARATOR
Intervention: Market formulation (Theobid)
Number of subjects: 6
Study 7763064 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 200 micrograms twice daily
Number of subjects: 20
Study 7763064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2305475 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient surgery (group 2)
Number of subjects: 73
Study 2305475 — intervention group
Group type: COMPARATOR
Intervention: Inpatient surgery (group 1)
Number of subjects: 73
Study 6104225 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymphoscintigraphy using intradermal injection of 100 muCi technetium‐99m antimony sulphide colloid in 0.1 ml buffer
Number of subjects: 30
Study 6104225 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymphoscintigraphy
Number of subjects: 30
Study 31122527 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified speculum application (109 patients, 124 cycles)
Number of subjects: 219
Study 31122527 — intervention group
Group type: COMPARATOR
Intervention: Conventional speculum application (110 patients, 132 cycles)
Number of subjects: 219
Study 31122527 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified speculum application
Number of subjects: 219
Study 31122527 — intervention group
Group type: COMPARATOR
Intervention: Conventional speculum application
Number of subjects: 219
Study 28258730 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid (ALA) oral supplementation
Number of subjects: 73
Study 28258730 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 73
Study 26021488 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA+EPA (4 g/day)
Number of subjects: 100
Study 26021488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 24333089 — intervention group
Group type: EXPERIMENTAL
Intervention: (C)ce(s) haplotype screening using allele-specific primer polymerase chain reactions
Number of subjects: 400
Study 22152402 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 60
Study 22152402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19436683 — intervention group
Group type: EXPERIMENTAL
Intervention: Singing classes
Number of subjects: 43
Study 19436683 — intervention group
Group type: COMPARATOR
Intervention: Handcraft work
Number of subjects: 43
Study 19436683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 15871484 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT2A inhibitor (sarpogrelate 300 mg/day)
Number of subjects: 40
Study 15871484 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (diclofenac 75 mg/day)
Number of subjects: 40
Study 12850609 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 62
Study 12850609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 10389358 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebrew version of the Buschke Selective Reminding Memory Test
Number of subjects: 24
Study 8905024 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 153
Study 8905024 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Tamoxifen
Number of subjects: 153
Study 8905024 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 153
Study 2057005 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTA)
Number of subjects: 23
Study 2057005 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 23
Study 6124268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 15
Study 6124268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg
Number of subjects: 15
Study 6124268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 160 mg
Number of subjects: 15
Study 6124268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6124268 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Nadolol
Number of subjects: 15
Study 6124268 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 15
Study 30989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with physicians and nursing professionals
Number of subjects: 82
Study 30989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians at different hierarchical levels
Number of subjects: 82
Study 30989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Group membership processes
Number of subjects: 82
Study 30989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intergroup boundaries
Number of subjects: 82
Study 30989682 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of clinicians
Number of subjects: 82
Study 28371642 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Faces Card Sorting Test (EFCST) with angry faces
Number of subjects: 80
Study 28371642 — intervention group
Group type: COMPARATOR
Intervention: Wisconsin Card Sorting Test (WCST)
Number of subjects: 80
Study 25240388 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + calcium hydroxide
Number of subjects: 20
Study 25240388 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide
Number of subjects: 20
Study 25240388 — intervention group
Group type: COMPARATOR
Intervention: Buckley's formocresol
Number of subjects: 20
Study 23482513 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread
Number of subjects: 11
Study 23482513 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole wheat buttermilk bread
Number of subjects: 11
Study 23482513 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain bread
Number of subjects: 11
Study 23482513 — intervention group
Group type: COMPARATOR
Intervention: Pumpernickel rye bread (control)
Number of subjects: 11
Study 23482513 — intervention group
Group type: EXPERIMENTAL
Intervention: All breads
Number of subjects: 11
Study 21147153 — intervention group
Group type: EXPERIMENTAL
Intervention: PriMa intervention (nine guided lessons with special posters and group discussions)
Number of subjects: 1553
Study 18618462 — intervention group
Group type: EXPERIMENTAL
Intervention: de Quervain's screening tool (DQST)
Number of subjects: 93
Study 16950469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (infused from 5 to 40 microg/kg/min)
Number of subjects: 142
Study 16950469 — intervention group
Group type: COMPARATOR
Intervention: Control group (115 patients without dobutamine-induced obstruction)
Number of subjects: 142
Study 15052623 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased resting mean arterial pressure (MAP) by 22% through sustained voluntary contraction of contralateral elbow flexors
Number of subjects: 8
Study 15052623 — intervention group
Group type: COMPARATOR
Intervention: Intermittent supramaximal electrical stimulation of the median nerve at 20 Hz for 2 min
Number of subjects: 8
Study 11171670 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation during ischemic fatigue (IF)
Number of subjects: 0
Study 11171670 — intervention group
Group type: COMPARATOR
Intervention: Rest condition without creatine supplementation
Number of subjects: 0
Study 11171670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic fatigue (IF) condition
Number of subjects: 0
Study 11171670 — intervention group
Group type: EXPERIMENTAL
Intervention: (1)H-MRS studies
Number of subjects: 0
Study 9389922 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone (20 mg i.v.)
Number of subjects: 110
Study 9389922 — intervention group
Group type: COMPARATOR
Intervention: Granisetron plus placebo (matching placebo)
Number of subjects: 110
Study 7936823 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intakes ranging from 2.25 to 3.9 g.kg‐1.d‐1 and energy intakes ranging from 115 to 147 kcal.kg‐1.d‐1
Number of subjects: 44
Study 7936823 — intervention group
Group type: COMPARATOR
Intervention: Two groups with differing energy intakes
Number of subjects: 44
Study 2452392 — intervention group
Group type: EXPERIMENTAL
Intervention: COP-BLAM (5 cycles) and IMVP-16 (2 cycles) protocols
Number of subjects: 191
Study 2452392 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 191
Study 2452392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive polychemotherapy
Number of subjects: 191
Study 31848066 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model of in-hospital mortality based on prognostic variables (age, prosthetic valve IE, comorbidities, heart failure, renal failure, septic shock, Staphylococcus aureus, fungi, periannular complications, ventricular dysfunction, vegetations).
Number of subjects: 1135
Study 28521546 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 160
Study 28521546 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet almond oil
Number of subjects: 160
Study 28521546 — intervention group
Group type: COMPARATOR
Intervention: Base cream
Number of subjects: 160
Study 28521546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 160
Study 27161619 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple (provisional T-stenting) strategy
Number of subjects: 913
Study 24360368 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral cediranib 20mg
Number of subjects: 306
Study 24360368 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel chemotherapy
Number of subjects: 306
Study 22841551 — intervention group
Group type: EXPERIMENTAL
Intervention: AgION catheter
Number of subjects: 86
Study 22841551 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated catheter (Control)
Number of subjects: 86
Study 20636655 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 882
Study 20636655 — intervention group
Group type: COMPARATOR
Intervention: Continuous CATI
Number of subjects: 882
Study 17719167 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3g daily)
Number of subjects: 70
Study 17719167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 16634957 — intervention group
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine mineral and a collagen membrane
Number of subjects: 120
Study 16634957 — intervention group
Group type: COMPARATOR
Intervention: Papilla preservation flaps alone (Control)
Number of subjects: 120
Study 14645968 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) increase
Number of subjects: 0
Study 11030401 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hyperfractionated irradiation (20 Gy)
Number of subjects: 28
Study 9167772 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-drug parenteral polyestradiol phosphate (240 mg intramuscularly every second week for the first two months, then every fourth week)
Number of subjects: 30
Study 9167772 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 30
Study 9167772 — intervention group
Group type: COMPARATOR
Intervention: Estrogen treatment vs. Orchidectomy
Number of subjects: 30
Study 1493787 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional valproate (VPA)
Number of subjects: 0
Study 1493787 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release valproate (VPA-CR)
Number of subjects: 0
Study 1493787 — intervention group
Group type: COMPARATOR
Intervention: VPA and VPA-CR
Number of subjects: 0
Study 3730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Load perturbations (opposing the forthcoming movement)
Number of subjects: 0
Study 3730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Unload perturbations (assisting the forthcoming movement)
Number of subjects: 0
Study 3730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation size (large vs small)
Number of subjects: 0
Study 29326145 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital cardiac arrest (OHCA) survivors (n=270)
Number of subjects: 287
Study 29326145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-event working OHCA survivors (n=135)
Number of subjects: 287
Study 29326145 — intervention group
Group type: EXPERIMENTAL
Intervention: OHCA survivors with cognitive impairment (n=55)
Number of subjects: 287
Study 29326145 — intervention group
Group type: EXPERIMENTAL
Intervention: OHCA survivors
Number of subjects: 287
Study 29326145 — intervention group
Group type: COMPARATOR
Intervention: ST-segment-elevation myocardial infarction (STEMI) controls
Number of subjects: 287
Study 26844840 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 1147
Study 26844840 — intervention group
Group type: COMPARATOR
Intervention: Iodine-alcohol
Number of subjects: 1147
Study 24289108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily (QD)
Number of subjects: 108
Study 24289108 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg QD
Number of subjects: 108
Study 24289108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 108
Study 22781199 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (BUD) + nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + 0.05% budesonide (2 ml)
Number of subjects: 40
Study 22781199 — intervention group
Group type: COMPARATOR
Intervention: Nebulized 0.5% salbutamol (150 µg/kg) + 0.025% ipratropium bromide (1 ml) + saline (2 ml)
Number of subjects: 40
Study 19142560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound evaluation of suprascapular notch
Number of subjects: 50
Study 19142560 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler ultrasound
Number of subjects: 50
Study 17317135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold environment (‐18.0 degrees C, 39.2% relative humidity)
Number of subjects: 20
Study 17317135 — intervention group
Group type: COMPARATOR
Intervention: Standard environment (20.2 degrees C, 40.0% relative humidity)
Number of subjects: 20
Study 14748763 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone 800 mg
Number of subjects: 49
Study 14748763 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone 1200 mg
Number of subjects: 49
Study 14748763 — intervention group
Group type: COMPARATOR
Intervention: Dronedarone 1600 mg
Number of subjects: 49
Study 14748763 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 49
Study 14748763 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone (800‐1600 mg daily) added to metoprolol (200 mg daily)
Number of subjects: 49
Study 11606503 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose UDCA (20 mg/kg daily)
Number of subjects: 26
Study 11606503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9587719 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg (group 2)
Number of subjects: 291
Study 9587719 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg plus ketoprofen 100 mg and propacetamol 2 g (group 3)
Number of subjects: 291
Study 9587719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 1)
Number of subjects: 291
Study 7993155 — intervention group
Group type: EXPERIMENTAL
Intervention: High triglyceride level plus low HDL-C level
Number of subjects: 0
Study 7993155 — intervention group
Group type: COMPARATOR
Intervention: Low HDL-C level alone
Number of subjects: 0
Study 7993155 — intervention group
Group type: COMPARATOR
Intervention: High triglyceride level alone
Number of subjects: 0
Study 2683824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (2 mg.h‐1)
Number of subjects: 127
Study 2683824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 2683824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 127
Study 1150909 — intervention group
Group type: EXPERIMENTAL
Intervention: doxepin h.s.
Number of subjects: 40
Study 1150909 — intervention group
Group type: COMPARATOR
Intervention: doxepin q.i.d.
Number of subjects: 40
Study 30234805 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac crest bone graft harvested unilaterally through the primary midline incision.
Number of subjects: 90
Study 24850775 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a rinse
Number of subjects: 0
Study 24850775 — intervention group
Group type: COMPARATOR
Intervention: 15 mL of 0.2% chlorhexidine (CHX) for 60 s as a swab
Number of subjects: 0
Study 24060277 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue lupin fibre (25 g/d)
Number of subjects: 92
Study 24060277 — intervention group
Group type: EXPERIMENTAL
Intervention: White lupin fibre (25 g/d)
Number of subjects: 92
Study 24060277 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya fibre (25 g/d)
Number of subjects: 92
Study 24060277 — intervention group
Group type: COMPARATOR
Intervention: Citrus fibre (25 g/d)
Number of subjects: 92
Study 21288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus high-dose rifampicin (15 mg/kg/day) and levofloxacin
Number of subjects: 750
Study 21288325 — intervention group
Group type: COMPARATOR
Intervention: Standard Vietnamese national guideline treatment for tuberculous meningitis
Number of subjects: 750
Study 21288325 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus high-dose rifampicin and levofloxacin
Number of subjects: 750
Study 19424750 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia (LA)
Number of subjects: 40
Study 19424750 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 22986471 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (EG)
Number of subjects: 50
Study 22986471 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study 15800226 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (target international normalized ratio, 2.0 to 3.0)
Number of subjects: 569
Study 15800226 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (1300 mg per day)
Number of subjects: 569
Study 12853534 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine silver sulfadiazine (CSS) CVC
Number of subjects: 1000
Study 12853534 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin-minocycline (RM) CVC
Number of subjects: 1000
Study 12853534 — intervention group
Group type: COMPARATOR
Intervention: Uncoated CVC
Number of subjects: 1000
Study 10568210 — intervention group
Group type: EXPERIMENTAL
Intervention: Lem1 (natural compound derived from lemon oil)
Number of subjects: 0
Study 10568210 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8550648 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 8550648 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0
Study 8550648 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Morphine and Methylprednisolone
Number of subjects: 0
Study 8550648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 0
Study 2191764 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy plus tamoxifen (RT-TAM)
Number of subjects: 427
Study 2191764 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (RT)
Number of subjects: 427
Study 2191764 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT)
Number of subjects: 427
Study 2191764 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen (CT-TAM)
Number of subjects: 427
Study 2191764 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 427
Study 2191764 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy or tamoxifen
Number of subjects: 427
Study 34186 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 34186 — intervention group
Group type: COMPARATOR
Intervention: Clorazepate (15 mg)
Number of subjects: 0
Study 34186 — intervention group
Group type: COMPARATOR
Intervention: L-dopa (1000 mg)
Number of subjects: 0
Study 34186 — intervention group
Group type: COMPARATOR
Intervention: Thyrotropin-releasing hormone (TRH) (2 mg)
Number of subjects: 0
Study 30135176 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy with engineered multispecificity
Number of subjects: 0
Study 30135176 — intervention group
Group type: EXPERIMENTAL
Intervention: Approaches to overcome antigen escape
Number of subjects: 0
Study 26386751 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood control peripheral intravenous catheter
Number of subjects: 152
Study 26386751 — intervention group
Group type: COMPARATOR
Intervention: Standard peripheral intravenous catheter
Number of subjects: 152
Study 25802955 — intervention group
Group type: EXPERIMENTAL
Intervention: MT + MG
Number of subjects: 48
Study 25802955 — intervention group
Group type: COMPARATOR
Intervention: MT + sham
Number of subjects: 48
Study 25802955 — intervention group
Group type: COMPARATOR
Intervention: MT
Number of subjects: 48
Study 23649374 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride, 1 mmol/l, perfused for 5 min
Number of subjects: 14
Study 23649374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 14
Study 20936369 — intervention group
Group type: EXPERIMENTAL
Intervention: 9c,11t-CLA
Number of subjects: 22
Study 20936369 — intervention group
Group type: COMPARATOR
Intervention: 10t,12c-CLA
Number of subjects: 22
Study 20936369 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid (9c-18:1)
Number of subjects: 22
Study 18804084 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based curriculum for computer and Internet skills
Number of subjects: 0